$345 Million is the total value of Cormorant Asset Management, LP's 37 reported holdings in Q4 2013. The portfolio turnover from Q3 2013 to Q4 2013 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDVN | New | MEDIVATION INC | $34,903,000 | – | 546,900 | +100.0% | 10.13% | – |
| CBST | New | CUBIST PHARMACEUTICALS INC | $27,548,000 | – | 400,000 | +100.0% | 8.00% | – |
| KERX | New | KERYX BIOPHARMACEUTICALS | $22,015,000 | – | 1,700,000 | +100.0% | 6.39% | – |
| DYAX | New | DYAX CORP | $21,475,000 | – | 2,850,000 | +100.0% | 6.23% | – |
| PBYI | New | PUMA BIOTECHNOLOGY INC | $20,706,000 | – | 200,000 | +100.0% | 6.01% | – |
| CELG | New | CELGENE CORP | $20,276,000 | – | 120,000 | +100.0% | 5.88% | – |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $19,992,000 | – | 800,000 | +100.0% | 5.80% | – |
| IDIX | New | IDENIX PHARMACEUTICALS INC | $17,492,000 | – | 2,925,000 | +100.0% | 5.08% | – |
| GERN | New | GERON CORP | $16,103,000 | – | 3,397,156 | +100.0% | 4.67% | – |
| ALNY | New | ALNYLAM PHARMACEUTICALS INC | $16,075,000 | – | 250,000 | +100.0% | 4.66% | – |
| BMY | New | BRISTOL-MYERS SQUIBB CO | $14,351,000 | – | 270,000 | +100.0% | 4.16% | – |
| ARWR | New | ARROWHEAD RESEARCH CORP | $10,801,000 | – | 995,500 | +100.0% | 3.14% | – |
| DXCM | New | DEXCOM INC | $10,623,000 | – | 300,000 | +100.0% | 3.08% | – |
| RCPT | New | RECEPTOS INC | $10,147,000 | – | 350,000 | +100.0% | 2.94% | – |
| ARRY | New | ARRAY BIOPHARMA INC | $8,768,000 | – | 1,750,000 | +100.0% | 2.54% | – |
| ACRX | New | ACELRX PHARMACEUTICALS INC | $8,483,000 | – | 750,000 | +100.0% | 2.46% | – |
| TSRO | New | TESARO INC | $8,472,000 | – | 300,000 | +100.0% | 2.46% | – |
| CLVS | New | CLOVIS ONCOLOGY INC | $7,190,000 | – | 119,300 | +100.0% | 2.09% | – |
| BMRN | New | BIOMARIN PHARMACEUTICAL INC | $7,035,000 | – | 100,000 | +100.0% | 2.04% | – |
| New | ALKERMES PLC | $6,099,000 | – | 150,000 | +100.0% | 1.77% | – | |
| AMAG | New | AMAG PHARMACEUTICALS INC | $6,070,000 | – | 250,000 | +100.0% | 1.76% | – |
| PODD | New | INSULET CORP | $5,565,000 | – | 150,000 | +100.0% | 1.62% | – |
| NVAX | New | NOVAVAX INC | $5,120,000 | – | 1,000,000 | +100.0% | 1.49% | – |
| PCRX | New | PACIRA PHARMACEUTICALS INC | $2,875,000 | – | 50,000 | +100.0% | 0.83% | – |
| SGMO | New | SANGAMO BIOSCIENCES INC | $2,309,000 | – | 166,200 | +100.0% | 0.67% | – |
| KPTI | New | KARYOPHARM THERAPEUTICS INC | $2,292,000 | – | 100,000 | +100.0% | 0.66% | – |
| CMRX | New | CHIMERIX INC | $2,161,000 | – | 143,000 | +100.0% | 0.63% | – |
| BCRX | New | BIOCRYST PHARMACEUTICALS | $2,037,000 | – | 268,000 | +100.0% | 0.59% | – |
| PTLA | New | PORTOLA PHARMACEUTICALS INC | $1,931,000 | – | 75,000 | +100.0% | 0.56% | – |
| OSIR | New | OSIRIS THERAPEUTICS INC NEW | $1,733,000 | – | 107,800 | +100.0% | 0.50% | – |
| XNPT | New | XENOPORT INC | $1,150,000 | – | 200,000 | +100.0% | 0.33% | – |
| RGLS | New | REGULUS THERAPEUTICS INC | $739,000 | – | 100,000 | +100.0% | 0.21% | – |
| PTCT | New | PTC THERAPEUTICS INC | $489,000 | – | 28,800 | +100.0% | 0.14% | – |
| MNTA | New | MOMENTA PHARMACEUTICALS INC | $490,000 | – | 27,700 | +100.0% | 0.14% | – |
| DNDNQ | New | DENDREON CORP | $449,000 | – | 150,000 | +100.0% | 0.13% | – |
| FPRX | New | FIVE PRIME THERAPEUTICS INC | $336,000 | – | 20,000 | +100.0% | 0.10% | – |
| ENTA | New | ENANTA PHARMACEUTICALS INC | $273,000 | – | 10,000 | +100.0% | 0.08% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| APELLIS PHARMACEUTICALS INC | 26 | Q1 2024 | 8.6% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| ROCKET PHARMACEUTICALS, INC | 25 | Q1 2024 | 2.4% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Rapport Therapeutics, Inc. | June 20, 2024 | 1,283,673 | - |
| CytomX Therapeutics, Inc. | May 13, 2024 | 5,750,000 | - |
| TScan Therapeutics, Inc. | April 29, 2024 | 2,500,000 | - |
| Immuneering Corp | April 15, 2024 | 561,128 | - |
| Ventyx Biosciences, Inc. | March 21, 2024 | 3,670,000 | - |
| Corbus Pharmaceuticals Holdings, Inc. | March 18, 2024 | 2,025,000 | - |
| 89bio, Inc.Sold out | February 14, 2024 | 0 | - |
| Aerovate Therapeutics, Inc.Sold out | February 14, 2024 | 0 | - |
| ALPINE IMMUNE SCIENCES, INC. | February 14, 2024 | 2,550,000 | - |
| Ambrx Biopharma, Inc. | February 14, 2024 | 8,725,040 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-09-25 |
| 4 | 2024-09-24 |
| N-PX | 2024-08-30 |
| 13F-HR | 2024-08-14 |
| SC 13G | 2024-06-20 |
| 4 | 2024-06-13 |
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-13 |
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.